Tuberculosis (TB) Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: October 07, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 1.8 billion |
|
Revenue forecast in 2030 |
US$ 2.58 billion |
|
Growth Rate |
CAGR of 4.10% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
Type, End User, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global tuberculosis (TB) diagnostics market was valued at US$ 1.8 billion in 2021 and is expected to register a revenue CAGR of 4.10% during the forecast period.
Market Fundamentals
Tuberculosis (TB) is a highly contagious and infectious disease caused by mycobacterium tuberculosis bacteria (MTB). Tuberculosis bacteria primarily attack the lungs but can also infect any body part, i.e., the nervous system, glands, bones, organs, etc. Tuberculosis (TB) is contracted through droplets spread in the air via sneezes and coughs by an infected person. The primary infected person experiences pain in the chest, coughing up blood or mucus, breathlessness, high fever, night sweats, fatigue or weakness, loss of appetite, and sudden weight loss. For diagnosing tuberculosis (TB), various methods such as culture and sensitivity tests, radiographic tests (X-Ray, CT- SCAN), microscopy, molecular testing, antigen testing, genetic testing, and drug resistance tests are available.
[94858433]
Market Dynamics
Global tuberculosis (TB) diagnostics market revenue growth is driven by the increasing prevalence of tuberculosis, government regulation on cost, government initiatives for TB-free campaigns, favorable reimbursement policies, and rising awareness about tuberculosis. The growing number of HIV and AIDS patients is fueling revenue growth of the global tuberculosis (TB) diagnostics market as they are more vulnerable to tuberculosis and other diseases because of their low immunity. Moreover, technological advancements, the introduction of a novel diagnostic methodology for the diagnosis of tuberculosis, and high numbers of players are fueling global tuberculosis (TB) diagnostics market. However, expensive reagents, the high cost of genome sequencing and molecular testing, and testing analyzers are expected to restrain the market revenue growth to some extent.
Market Ecosystem
The global tuberculosis (TB) diagnostics market is analyzed from four perspectives: type, end user, and region.
Tuberculosis (TB) Diagnostics Market by Type
[8980945]
Based on test, the global tuberculosis (TB) diagnostics market is segmented into culture and species identification, radiographic tests, microscopy, molecular testing, antigen testing, genetic testing, and drug resistance testing.
Molecular testing amplifies the viral RNA by making multiple copies of viral infection, making diagnosis more precise and easier to quantify viral load detection. Molecular testing is leading the global tuberculosis diagnostic market in terms of revenue share owing to the accurate qualitative and quantitative viral load screening to understand the severity of infection. Additionally, technological advancement, less turnaround time, high sensitivity, and high specificity are contributing to the growth of the molecular diagnostics segment.
The genetic testing segment is expected to register the highest revenue growth during the forecast period owing to precise diagnosis and early screening of TB.
Tuberculosis (TB) Diagnostics Market by End User
Based on end-user, the global tuberculosis (TB) diagnostics market is segmented into hospitals & clinics, and diagnostic laboratories.
Hospitals and clinics are crucial in primary symptom analysis and prescribing confirmatory tests. Hospitals and clinics are leading global tuberculosis (TB) diagnostics market in terms of revenue share owing to the increasing prevalence of tuberculosis (TB), and high patient footfall for diagnosis and treatment.
Tuberculosis (TB) Diagnostics Market by Region
Based on the region, the global tuberculosis (TB) diagnostics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
In terms of revenue share, North America is leading the global tuberculosis (TB) diagnostics market, followed by the Asia Pacific.
The large revenue share of North America in the global market can be attributed to high expenditure on healthcare, technological advancement, developed infrastructure, and the adoption of novel technology to diagnose tuberculosis (TB).
The Asia Pacific is also expected to register the highest revenue growth owing to its large population, increasing awareness about tuberculosis, developing infrastructure, and emerging diagnostics companies. Additionally, growing regional market players, the presence of untapped opportunities, and government initiatives for tuberculosis diagnosis and treatment contribute to the revenue growth of the Asia Pacific tuberculosis (TB) diagnostics market.
Competitive Landscape
The prominent players operating in the global tuberculosis (TB) diagnostics market are:
Strategic Developments
The Asia Pacific is expected to register the highest revenue growth during the forecast period and can be considered the key revenue growth region.
The introduction of novel diagnostic technologies, the increasing prevalence of tuberculosis, and government initiatives for tuberculosis diagnostics and treatment are the major factors driving the revenue growth of the global tuberculosis diagnostics market.
The high cost of genome sequencing and molecular testing, expensive reagents, and testing analyzers are the major factors restraining the revenue growth of the global tuberculosis (TB) diagnostics market.
Abbott Laboratories Inc., Becton, Dickinson, and Company, BioMérieux SA, and Danaher Corporation are among the key companies operating in the global tuberculosis (TB) diagnostics market.
*Insights on financial performance is subject to availability of information in public domain